I am a
Home I AM A Search Login

Papers of the Week


PLoS One



A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.


Wohlford GF, Buckley LF, Kadariya D, Park T, Chiabrando J G, Carbone S, Mihalick V, Halquist MS, Pearcy A, Austin D, Gelber C, Abbate A, Van Tassell B
PLoS One. 2021; 16(5):e0247357.
PMID: 33956804.


Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitrypsin.